- Home
- GELS vs ZBIO Comparison
GELS vs ZBIO Comparison
Compare GELS & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GELS
- ZBIO
- Stock Information
- Founded
- GELS 2018
- ZBIO 2019
- Country
- GELS Australia
- ZBIO United States
- Employees
- GELS N/A
- ZBIO N/A
- Industry
- GELS
- ZBIO
- Sector
- GELS
- ZBIO
- Exchange
- GELS NYSE
- ZBIO NYSE
- Market Cap
- GELS 15.9M
- ZBIO 389.2M
- IPO Year
- GELS 2024
- ZBIO 2024
- Fundamental
- Price
- GELS $1.81
- ZBIO $11.18
- Analyst Decision
- GELS
- ZBIO Strong Buy
- Analyst Count
- GELS 0
- ZBIO 7
- Target Price
- GELS N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- GELS 232.4K
- ZBIO 175.9K
- Earning Date
- GELS 02-15-2025
- ZBIO 08-16-2025
- Dividend Yield
- GELS N/A
- ZBIO N/A
- EPS Growth
- GELS N/A
- ZBIO N/A
- EPS
- GELS N/A
- ZBIO N/A
- Revenue
- GELS $233,830.00
- ZBIO $15,000,000.00
- Revenue This Year
- GELS N/A
- ZBIO $206.00
- Revenue Next Year
- GELS N/A
- ZBIO $41.92
- P/E Ratio
- GELS N/A
- ZBIO N/A
- Revenue Growth
- GELS 10.19
- ZBIO N/A
- 52 Week Low
- GELS $0.77
- ZBIO $5.83
- 52 Week High
- GELS $5.50
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- GELS N/A
- ZBIO N/A
- Support Level
- GELS N/A
- ZBIO N/A
- Resistance Level
- GELS N/A
- ZBIO N/A
- Average True Range (ATR)
- GELS 0.00
- ZBIO 0.00
- MACD
- GELS 0.00
- ZBIO 0.00
- Stochastic Oscillator
- GELS 0.00
- ZBIO 0.00
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.